Skip to main content

27-06-2018 | Triple-negative breast cancer | Article

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

Fasching PA et al. J Clin Oncol 2018; JCO2017772285. doi:10.1200/JCO.2017.77.2285

Please log in to get access to this content

Related topics